Phaseline

Targets › PTK7

PTK7 (Inactive tyrosine-protein kinase 7): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 4 Phase 1; Oncology; next expected readout Jul 2027.

Inactive tyrosine kinase involved in the Wnt signaling pathway. Component of both the non-canonical (also known as the Wnt/planar cell polarity signaling) and the canonical Wnt signaling pathways. (UniProt, Q13308)

Open in Phaseline: the race on PTK7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
IDEAYA BiosciencesIDE034
Bispecific antibody targeting B7-H3 and PTK7
B7H3, PTK7Phase 1Esophageal Squamous Cell CarcinomaJul 2027
Day One BiopharmaceuticalsDAY301
PTK7-directed antibody-drug conjugate
PTK7Phase 1Advanced or Metastatic Solid TumorsDec 2027
Kivu BioscienceKIVU-107
PTK7-directed antibody-drug conjugate
PTK7Phase 1Advance Solid TumorsMar 2028
Whitehawk TherapeuticsHWK-007
PTK7-directed antibody-drug conjugate
PTK7Phase 1Endometrial CancerOct 2028

Conditions

Esophageal Squamous Cell Carcinoma (1) Endometrial Cancer (1) Advanced or Metastatic Solid Tumors (1) Advance Solid Tumors (1)

Modalities

small molecule (4)

Companies

IDEAYA Biosciences (1) Whitehawk Therapeutics (1) Day One Biopharmaceuticals (1) Kivu Bioscience (1)

Related targets

B7H3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.